LLY

1,036.74

+2.99%↑

JNJ

229.66

-0.1%↓

ABBV

214.11

+0.75%↑

UNH

384.59

-0.16%↓

AZN

188.63

+0.6%↑

LLY

1,036.74

+2.99%↑

JNJ

229.66

-0.1%↓

ABBV

214.11

+0.75%↑

UNH

384.59

-0.16%↓

AZN

188.63

+0.6%↑

LLY

1,036.74

+2.99%↑

JNJ

229.66

-0.1%↓

ABBV

214.11

+0.75%↑

UNH

384.59

-0.16%↓

AZN

188.63

+0.6%↑

LLY

1,036.74

+2.99%↑

JNJ

229.66

-0.1%↓

ABBV

214.11

+0.75%↑

UNH

384.59

-0.16%↓

AZN

188.63

+0.6%↑

LLY

1,036.74

+2.99%↑

JNJ

229.66

-0.1%↓

ABBV

214.11

+0.75%↑

UNH

384.59

-0.16%↓

AZN

188.63

+0.6%↑

Search

Medtronic PLC

Deschisă

SectorSănătate

77.33 -0.26

Rezumat

Modificarea prețului

24h

Curent

Minim

76.81

Maxim

78.2

Indicatori cheie

By Trading Economics

Venit

-231M

1.1B

Vânzări

57M

9B

P/E

Medie Sector

21.598

49.701

EPS

0.89

Randament dividend

3.72

Marjă de profit

12.675

Angajați

95,000

EBITDA

124M

2.5B

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+35.04% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

3.72%

2.39%

Următoarele câștiguri

3 iun. 2026

Data viitoare de dividende

10 iul. 2026

Următoarea dată ex-dividende

26 iun. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-28B

99B

Deschiderea anterioară

77.59

Închiderea anterioară

77.33

Sentimentul știrilor

By Acuity

23%

77%

49 / 345 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bearish Evidence

Medtronic PLC Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

20 mai 2026, 13:49 UTC

Achiziții, Fuziuni, Preluări

Medtronic to Buy SPR Therapeutics for About $650 Million

10 mar. 2026, 11:19 UTC

Achiziții, Fuziuni, Preluări

Medtronic to Buy Scientia Vascular in $550 Million Deal

17 feb. 2026, 12:43 UTC

Câștiguri

Medtronic 3Q Profit Falls Despite Higher Revenue

20 mai 2026, 13:15 UTC

Achiziții, Fuziuni, Preluări

Medtronic Announces Intent To Acquire SPR Therapeutics, Inc., Expanding Care Options For People Living With Chronic Pain >MDT

20 mai 2026, 13:15 UTC

Achiziții, Fuziuni, Preluări

Medtronic to Buy SPR Therapeutics for About $650 Million in Cash >MDT

22 apr. 2026, 11:27 UTC

Câștiguri

Intuitive Surgical Earnings Show Big Beats Don't Always Spark Stock Rallies -- Barrons.com

20 apr. 2026, 11:50 UTC

Achiziții, Fuziuni, Preluări

Medtronic Completes Acquisition Of CathWorks, Expanding Its Leadership In Transforming Care For Patients With Cardiovascular Disease >MDT

24 mar. 2026, 20:59 UTC

Câștiguri

Medtronic PLC Cuts FY26 View To Adj EPS $5.50-Adj EPS $5.54 >MDT

10 mar. 2026, 10:46 UTC

Achiziții, Fuziuni, Preluări

Medtronic: Scientia Deal Complements Neurovascular Portfolio >MDT

10 mar. 2026, 10:46 UTC

Achiziții, Fuziuni, Preluări

Medtronic: Scientia Deal Includes Potential Undisclosed Earn-Out, Milestone Payments >MDT

10 mar. 2026, 10:45 UTC

Achiziții, Fuziuni, Preluări

Medtronic: Scientia Vascular Acquisition Valued at $550 Million >MDT

10 mar. 2026, 10:45 UTC

Achiziții, Fuziuni, Preluări

Medtronic to Acquire Scientia Vascular >MDT

17 feb. 2026, 21:21 UTC

Câștiguri

These Stocks Are Today's Movers: Paramount, Masimo, Medtronic, Kyndryl, eToro, Genuine Parts, Southwest, and More -- Barrons.com

17 feb. 2026, 18:11 UTC

Câștiguri

Medtronic Posts Better-Than-Expected Earnings. Here's Why the Stock Is Falling. -- Barrons.com

17 feb. 2026, 14:48 UTC

Câștiguri

Medtronic Posts Better-Than-Expected Earnings. Here's Why the Stock Is Falling. -- Barrons.com

17 feb. 2026, 13:00 UTC

Câștiguri

Medtronic Posts Better-Than-Expected Earnings. Here's Why the Stock Is Falling. -- Barrons.com

17 feb. 2026, 12:05 UTC

Câștiguri

Medtronic Posts Better-Than-Expected Earnings. Here's Why the Stock Is Falling. -- Barrons.com

17 feb. 2026, 11:47 UTC

Câștiguri

Medtronic Sees 2026 EPS up 4.5%, Excluding Potential Impact From Tariffs >MDT

17 feb. 2026, 11:47 UTC

Câștiguri

Medtronic Still Sees FY26 Organic Revenue Up About 5.5% >MDT

17 feb. 2026, 11:46 UTC

Câștiguri

Medtronic FY26 View Includes Potential Impact From Tariffs of About $185M >MDT

17 feb. 2026, 11:46 UTC

Câștiguri

Medtronic Backs FY26 View of Adj EPS $5.62-Adj EPS $5.66 >MDT

17 feb. 2026, 11:46 UTC

Câștiguri

Medtronic Reiterates FY26 Organic Rev Growth, EPS Guidance >MDT

17 feb. 2026, 11:45 UTC

Câștiguri

Medtronic 3Q Adj EPS $1.36 >MDT

17 feb. 2026, 11:45 UTC

Câștiguri

Medtronic 3Q Neuroscience Portfolio Rev $2.56B >MDT

17 feb. 2026, 11:45 UTC

Câștiguri

Medtronic 3Q Organic Revenue Up 6.0% >MDT

17 feb. 2026, 11:45 UTC

Câștiguri

Medtronic 3Q Sales $9.02B >MDT

17 feb. 2026, 11:45 UTC

Câștiguri

Medtronic 3Q Diabetes Rev $796M >MDT

17 feb. 2026, 11:45 UTC

Câștiguri

Medtronic 3Q Cardiovascular Portfolio Rev $3.46B >MDT

17 feb. 2026, 11:45 UTC

Câștiguri

Medtronic 3Q Medical Surgical Portfolio Rev $2.17B >MDT

17 feb. 2026, 11:45 UTC

Câștiguri

Medtronic 3Q Net $1.14B >MDT

Comparație

Modificare preț

Medtronic PLC Așteptări

Obiectiv de preț

By TipRanks

35.04% sus

Prognoză pe 12 luni

Medie 105.53 USD  35.04%

Maxim 120 USD

Minim 86 USD

În baza a 17 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruMedtronic PLC - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

17 ratings

11

Cumpărare

6

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

83.26 / 84.875Suport & Rezistență

Termen scurt

Weak Bearish Evidence

Termen mediu

Bullish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

49 / 345 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Medtronic PLC

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.
help-icon Live chat